Ma Songjiang's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed Feb 19, 2025
- Accession no.
- 0001140361-25-005113
- Filed
- Feb 19, 2025
- Trade date
- Feb 14-18, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $48.9K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | Common Stock | SSaleDisposed | −2,000 | $11.94 | −$23,880 | 2,869,260 | Indirect | |
| Feb 18, 2025 | Common Stock | SSaleDisposed | −2,000 | $12.49 | −$24,980 | 2,867,260 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.